Literature DB >> 10076486

Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group.

H S Jafari1, W G Adams, K A Robinson, B D Plikaytis, J D Wenger.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the effectiveness of Haemophilus influenzae type b (Hib) conjugate vaccines among children aged 2 to 18 months and to determine risk factors for invasive Hib disease during a period of declining incidence (1991-1994).
METHODS: A prospective population-based case-control study was conducted in a multistate US population of 15.5 million. A laboratory-based active surveillance system was used for case detection.
RESULTS: In a multivariate analysis, having a single-parent mother (odds ratio [OR] = 4.3, 95% confidence interval [CI] = 1.2, 14.8) and household crowding (OR = 3.5, 95% CI = 1.03, 11.7) were risk factors for Hib disease independent of vaccination status. After adjustment for these risk factors, the protective efficacy of 2 or more Hib vaccine doses was 86% (95% CI = 16%, 98%). Among undervaccinated subjects, living with a smoker (P = .02) and several indicators of lower socioeconomic status were risk factors for Hib disease.
CONCLUSIONS: Hib disease still occurs at low levels in the United States, predominantly in socioeconomically disadvantaged populations. Low immunization coverage may facilitate continuing transmission of Hib. Special efforts to achieve complete and timely immunization in disadvantaged populations are needed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076486      PMCID: PMC1508617          DOI: 10.2105/ajph.89.3.364

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  21 in total

1.  Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

Authors:  S B Black; H R Shinefield; B Fireman; R Hiatt; M Polen; E Vittinghoff
Journal:  Pediatr Infect Dis J       Date:  1991-02       Impact factor: 2.129

2.  Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group.

Authors:  J D Wenger; R Pierce; K A Deaver; B D Plikaytis; R R Facklam; C V Broome
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

3.  Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines.

Authors:  H Peltola; T Kilpi; M Anttila
Journal:  Lancet       Date:  1992-09-05       Impact factor: 79.321

4.  Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group.

Authors:  S B Black; H R Shinefield
Journal:  Pediatr Infect Dis J       Date:  1992-08       Impact factor: 2.129

5.  The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.

Authors:  M Santosham; M Wolff; R Reid; M Hohenboken; M Bateman; J Goepp; M Cortese; D Sack; J Hill; W Newcomer
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

6.  Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine.

Authors:  A K Takala; J Eskola; M Leinonen; H Käyhty; A Nissinen; E Pekkanen; P H Mäkelä
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

7.  Risk factors for primary invasive Haemophilus influenzae disease: increased risk from day care attendance and school-aged household members.

Authors:  G R Istre; J S Conner; C V Broome; A Hightower; R S Hopkins
Journal:  J Pediatr       Date:  1985-02       Impact factor: 4.406

8.  Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era.

Authors:  W G Adams; K A Deaver; S L Cochi; B D Plikaytis; E R Zell; C V Broome; J D Wenger
Journal:  JAMA       Date:  1993-01-13       Impact factor: 56.272

9.  Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors.

Authors:  S L Cochi; D W Fleming; A W Hightower; K Limpakarnjanarat; R R Facklam; J D Smith; R K Sikes; C V Broome
Journal:  J Pediatr       Date:  1986-06       Impact factor: 4.406

10.  Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease.

Authors:  K M Bisgard; A Kao; J Leake; P M Strebel; B A Perkins; M Wharton
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

View more
  5 in total

1.  Characterization of encapsulated and noncapsulated Haemophilus influenzae and determination of phylogenetic relationships by multilocus sequence typing.

Authors:  Emma Meats; Edward J Feil; Suzanna Stringer; Alison J Cody; Richard Goldstein; J Simon Kroll; Tanja Popovic; Brian G Spratt
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 2.  Association of secondhand smoke exposure with pediatric invasive bacterial disease and bacterial carriage: a systematic review and meta-analysis.

Authors:  Chien-Chang Lee; Nicole A Middaugh; Stephen R C Howie; Majid Ezzati
Journal:  PLoS Med       Date:  2010-12-07       Impact factor: 11.069

3.  Structure and function of Hib pili from Haemophilus influenzae type b.

Authors:  Xiang-Qi Mu; Edward H Egelman; Esther Bullitt
Journal:  J Bacteriol       Date:  2002-09       Impact factor: 3.490

4.  Haemophilus influenzae type b (Hib) seroprevalence in France: impact of vaccination schedules.

Authors:  Muhamed-Kheir Taha; Ala-Eddine Deghmane; Eva Hong; Aude Terrade; Mélanie Denizon; Myriam Aouiti-Trabelsi; Michaël Falguières
Journal:  BMC Infect Dis       Date:  2021-07-30       Impact factor: 3.090

5.  Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands.

Authors:  Joske Hoes; Anna G C Boef; Mirjam J Knol; Hester E de Melker; Liesbeth Mollema; Fiona R M van der Klis; Nynke Y Rots; Debbie van Baarle
Journal:  Front Public Health       Date:  2018-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.